35 results
424B3
COYA
Coya Therapeutics Inc
24 Jun 24
Prospectus supplement
5:31pm
on the timelines we expect, if at all.
We do not currently own, lease or operate a principal laboratory, research and development or manufacturing facility … research and development, organizing and staffing our company, business planning and raising capital. We have funded our operations primarily through
8-K
EX-99.1
COYA
Coya Therapeutics Inc
9 May 24
Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results
4:20pm
Financial Results
As of March 31, 2024, Coya had cash and cash equivalents of $36.0 million.
Research and development (R&D) expenses were $3.1 million … million increase in our preclinical expenses and a $0.2 million increase in internal research and development expenses.
General and administrative
8-K
EX-99.1
ovor3qfb2rf c3u
19 Mar 24
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
8:21am
424B3
b6xtqvxi77uq2b2
16 Jan 24
Prospectus supplement
4:06pm
S-3
0mbd0ukh3vewm2pu
4 Jan 24
Shelf registration
4:46pm
8-K
EX-99.1
lua 9oztrvl
8 Nov 23
Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results
9:03am
8-K
EX-99.1
pr8ux
8 Aug 23
Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results
7:05am
DEF 14A
8kv5joil
19 May 23
Definitive proxy
4:31pm
10-Q
ioajw51
10 May 23
Quarterly report
7:14am
10-Q
EX-10.1
i2guf
10 May 23
Quarterly report
7:14am
8-K
EX-99.1
ov1agk
10 May 23
Coya Therapeutics, Inc. Provides Business Update and Reports Q1 2023 Unaudited Financial Results
7:11am
10-K
p99mcz dztwdnkir9
29 Mar 23
Annual report
4:08pm